Schizophrenia - Wiki-Pi

Symbols	Name 1	Name 2	Pathways 1 Hide	Pathways 2 Hide	Drugs 1 Hide	Drugs 2 Hide
CDC5L and PPFIA2	cell division cycle 5-like	protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 2	Processing of Capped Intron-Containing Pre-mRNA mRNA Splicing mRNA Splicing - Major Pathway	Dopamine Neurotransmitter Release Cycle Neurotransmitter Release Cycle Acetylcholine Neurotransmitter Release Cycle Norepinephrine Neurotransmitter Release Cycle Serotonin Neurotransmitter Release Cycle Glutamate Neurotransmitter Release Cycle Transmission across Chemical Synapses
CDC25A and IL3RA	cell division cycle 25A	interleukin 3 receptor, alpha (low affinity)	E2F mediated regulation of DNA replication Ubiquitin Mediated Degradation of Phosphorylated Cdc25A G2/M Checkpoints G2/M Transition G0 and Early G1 Cyclin E associated events during G1/S transition S Phase Cyclin B2 mediated events Cell Cycle, Mitotic Cyclin A/B1 associated events during G2/M transition G1/S Transition Activation of ATR in response to replication stress G1/S-Specific Transcription E2F-enabled inhibition of pre-replication complex formation p53-Independent DNA Damage Response Cell Cycle Checkpoints Cyclin A:Cdk2-associated events at S phase entry p53-Independent G1/S DNA damage checkpoint Mitotic G2-G2/M phases Mitotic G1-G1/S phases Polo-like kinase mediated events G1/S DNA Damage Checkpoints	Signaling by GPCR G-protein beta:gamma signalling Cytokine Signaling in Immune system GPCR downstream signaling Signaling by Interleukins Interleukin receptor SHC signaling G beta:gamma signalling through PI3Kgamma Interleukin receptor SHC signaling GPVI-mediated activation cascade Interleukin-2 signaling Platelet activation, signaling and aggregation Interleukin-3, 5 and GM-CSF signaling		Sargramostim
CDC42 and VRK2	cell division cycle 42	vaccinia related kinase 2	Signaling by GPCR Costimulation by the CD28 family Axon guidance DCC mediated attractive signaling Signaling by EGFRvIII in Cancer VEGFA-VEGFR2 Pathway Inactivation of Cdc42 and Rac Rho GTPase cycle EPHB-mediated forward signaling EPH-Ephrin signaling G alpha (12/13) signalling events Sema4D in semaphorin signaling Netrin-1 signaling Fcgamma receptor (FCGR) dependent phagocytosis Sema4D induced cell migration and growth-cone collapse Regulation of actin dynamics for phagocytic cup formation Innate Immune System EGFR downregulation CDO in myogenesis Semaphorin interactions CD28 co-stimulation Signaling by Ligand-Responsive EGFR Variants in Cancer Factors involved in megakaryocyte development and platelet production Signaling by Overexpressed Wild-Type EGFR in Cancer CD28 dependent Vav1 pathway Signaling by EGFR GPCR downstream signaling Myogenesis Signaling by VEGF Signaling by Rho GTPases Signaling by EGFR in Cancer GPVI-mediated activation cascade Platelet activation, signaling and aggregation Signaling by Robo receptor Adaptive Immune System
CDC42 and SYNE1	cell division cycle 42	spectrin repeat containing, nuclear envelope 1	Signaling by GPCR Costimulation by the CD28 family Axon guidance DCC mediated attractive signaling Signaling by EGFRvIII in Cancer VEGFA-VEGFR2 Pathway Inactivation of Cdc42 and Rac Rho GTPase cycle EPHB-mediated forward signaling EPH-Ephrin signaling G alpha (12/13) signalling events Sema4D in semaphorin signaling Netrin-1 signaling Fcgamma receptor (FCGR) dependent phagocytosis Sema4D induced cell migration and growth-cone collapse Regulation of actin dynamics for phagocytic cup formation Innate Immune System EGFR downregulation CDO in myogenesis Semaphorin interactions CD28 co-stimulation Signaling by Ligand-Responsive EGFR Variants in Cancer Factors involved in megakaryocyte development and platelet production Signaling by Overexpressed Wild-Type EGFR in Cancer CD28 dependent Vav1 pathway Signaling by EGFR GPCR downstream signaling Myogenesis Signaling by VEGF Signaling by Rho GTPases Signaling by EGFR in Cancer GPVI-mediated activation cascade Platelet activation, signaling and aggregation Signaling by Robo receptor Adaptive Immune System	Meiotic synapsis
CDC42 and PARD3	cell division cycle 42	par-3 family cell polarity regulator	Signaling by GPCR Costimulation by the CD28 family Axon guidance DCC mediated attractive signaling Signaling by EGFRvIII in Cancer VEGFA-VEGFR2 Pathway Inactivation of Cdc42 and Rac Rho GTPase cycle EPHB-mediated forward signaling EPH-Ephrin signaling G alpha (12/13) signalling events Sema4D in semaphorin signaling Netrin-1 signaling Fcgamma receptor (FCGR) dependent phagocytosis Sema4D induced cell migration and growth-cone collapse Regulation of actin dynamics for phagocytic cup formation Innate Immune System EGFR downregulation CDO in myogenesis Semaphorin interactions CD28 co-stimulation Signaling by Ligand-Responsive EGFR Variants in Cancer Factors involved in megakaryocyte development and platelet production Signaling by Overexpressed Wild-Type EGFR in Cancer CD28 dependent Vav1 pathway Signaling by EGFR GPCR downstream signaling Myogenesis Signaling by VEGF Signaling by Rho GTPases Signaling by EGFR in Cancer GPVI-mediated activation cascade Platelet activation, signaling and aggregation Signaling by Robo receptor Adaptive Immune System	Loss of Function of TGFBR2 in Cancer Cell junction organization TGFBR2 MSI Frameshift Mutants in Cancer TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) SMAD2/3 Phosphorylation Motif Mutants in Cancer Tight junction interactions Loss of Function of SMAD2/3 in Cancer TGFBR2 Kinase Domain Mutants in Cancer SMAD2/3 MH2 Domain Mutants in Cancer Loss of Function of SMAD4 in Cancer TGFBR1 KD Mutants in Cancer TGFBR1 LBD Mutants in Cancer Loss of Function of TGFBR1 in Cancer Cell-cell junction organization Signaling by TGF-beta Receptor Complex Signaling by TGF-beta Receptor Complex in Cancer SMAD4 MH2 Domain Mutants in Cancer
CDC42 and ARHGAP31	cell division cycle 42	Rho GTPase activating protein 31	Signaling by GPCR Costimulation by the CD28 family Axon guidance DCC mediated attractive signaling Signaling by EGFRvIII in Cancer VEGFA-VEGFR2 Pathway Inactivation of Cdc42 and Rac Rho GTPase cycle EPHB-mediated forward signaling EPH-Ephrin signaling G alpha (12/13) signalling events Sema4D in semaphorin signaling Netrin-1 signaling Fcgamma receptor (FCGR) dependent phagocytosis Sema4D induced cell migration and growth-cone collapse Regulation of actin dynamics for phagocytic cup formation Innate Immune System EGFR downregulation CDO in myogenesis Semaphorin interactions CD28 co-stimulation Signaling by Ligand-Responsive EGFR Variants in Cancer Factors involved in megakaryocyte development and platelet production Signaling by Overexpressed Wild-Type EGFR in Cancer CD28 dependent Vav1 pathway Signaling by EGFR GPCR downstream signaling Myogenesis Signaling by VEGF Signaling by Rho GTPases Signaling by EGFR in Cancer GPVI-mediated activation cascade Platelet activation, signaling and aggregation Signaling by Robo receptor Adaptive Immune System	Rho GTPase cycle Signaling by Rho GTPases
CDH13 and ADIPOQ	cadherin 13	adiponectin, C1Q and collagen domain containing	Cell junction organization Cell-cell junction organization Adherens junctions interactions	Transcriptional regulation of white adipocyte differentiation
CDH13 and MAPK6	cadherin 13	mitogen-activated protein kinase 6	Cell junction organization Cell-cell junction organization Adherens junctions interactions
CDK2 and KIF26B	cyclin-dependent kinase 2	kinesin family member 26B	CDK-mediated phosphorylation and removal of Cdc6 G2/M Checkpoints Activation of the pre-replicative complex Cellular Senescence Phosphorylation of proteins involved in G1/S transition by active Cyclin E:Cdk2 complexes G2/M Transition p53-Dependent G1/S DNA damage checkpoint Activation of the pre-replicative complex Orc1 removal from chromatin Cyclin E associated events during G1/S transition CDK-mediated phosphorylation and removal of Cdc6 p53-Dependent G1 DNA Damage Response Cyclin A/B1 associated events during G2/M transition G2 Phase Activation of ATR in response to replication stress G1/S Transition Removal of licensing factors from origins Mitotic G1-G1/S phases Switching of origins to a post-replicative state G1/S DNA Damage Checkpoints Meiotic recombination DNA Damage/Telomere Stress Induced Senescence Synthesis of DNA DNA Replication Pre-Initiation M/G1 Transition Regulation of DNA replication Senescence-Associated Secretory Phenotype (SASP) G0 and Early G1 S Phase Regulation of APC/C activators between G1/S and early anaphase Factors involved in megakaryocyte development and platelet production Cell Cycle, Mitotic APC/C-mediated degradation of cell cycle proteins SCF(Skp2)-mediated degradation of p27/p21 Orc1 removal from chromatin Regulation of mitotic cell cycle Cell Cycle Checkpoints SCF(Skp2)-mediated degradation of p27/p21 Cyclin A:Cdk2-associated events at S phase entry Mitotic G2-G2/M phases		Double Oxidized Cysteine 4-[5-(Trans-4-Aminocyclohexylamino)-3-Isopropylpyrazolo[1,5-a]Pyrimidin-7-Ylamino]-N,N-Dimethylbenzenesulfonamide Staurosporine Indirubin-3\'-Monoxime 4-(2,4-Dimethyl-Thiazol-5-Yl)-Pyrimidin-2-Ylamine Olomoucine 4-[(4-Imidazo[1,2-a]Pyridin-3-Ylpyrimidin-2-Yl)Amino]Benzenesulfonamide 2-Amino-6-Chloropyrazine 6-O-Cyclohexylmethyl Guanine N-[4-(2-Methylimidazo[1,2-a]Pyridin-3-Yl)-2-Pyrimidinyl]Acetamide 1-Amino-6-Cyclohex-3-Enylmethyloxypurine N-(5-Cyclopropyl-1h-Pyrazol-3-Yl)Benzamide Purvalanol [4-(2-Amino-4-Methyl-Thiazol-5-Yl)-Pyrimidin-2-Yl]-(3-Nitro-Phenyl)-Amine 5-{[(2-Amino-9h-Purin-6-Yl)Oxy]Methyl}-2-Pyrrolidinone 4-(2,4-Dimethyl-Thiazol-5-Yl)-Pyrimidin-2-Yl]-(4-Trifluoromethyl-Phenyl)-Amine Hymenialdisine (5-Chloropyrazolo[1,5-a]Pyrimidin-7-Yl)-(4-Methanesulfonylphenyl)Amine 4-(5-Bromo-2-Oxo-2h-Indol-3-Ylazo)-Benzenesulfonamide 4-(2,5-Dichloro-Thiophen-3-Yl)-Pyrimidin-2-Ylamine 4-[(6-Amino-4-Pyrimidinyl)Amino]Benzenesulfonamide 4-[3-Hydroxyanilino]-6,7-Dimethoxyquinazoline SU9516 3-Pyridin-4-Yl-2,4-Dihydro-Indeno[1,2-.C.]Pyrazole Flavopiridol (2e,3s)-3-Hydroxy-5\'-[(4-Hydroxypiperidin-1-Yl)Sulfonyl]-3-Methyl-1,3-Dihydro-2,3\'-Biindol-2\'(1\'h)-One 1-[(2-Amino-6,9-Dihydro-1h-Purin-6-Yl)Oxy]-3-Methyl-2-Butanol 4-((3r,4s,5r)-4-Amino-3,5-Dihydroxy-Hex-1-Ynyl)-5-Fluoro-3-[1-(3-Methoxy-1h-Pyrrol-2-Yl)-Meth-(Z)-Ylidene]-1,3-Dihydro-Indol-2-One Lysine Nz-Carboxylic Acid [2-Amino-6-(2,6-Difluoro-Benzoyl)-Imidazo[1,2-a]Pyridin-3-Yl]-Phenyl-Methanone Alsterpaullone N-[4-(2,4-Dimethyl-1,3-Thiazol-5-Yl)Pyrimidin-2-Yl]-N\'-Hydroxyimidoformamide N\'-(Pyrrolidino[2,1-B]Isoindolin-4-On-8-Yl)-N-(Pyridin-2-Yl)Urea 2-[Trans-(4-Aminocyclohexyl)Amino]-6-(Benzyl-Amino)-9-Cyclopentylpurine 4-[4-(4-Methyl-2-Methylamino-Thiazol-5-Yl)-Pyrimidin-2-Ylamino]-Phenol 3-[4-(2,4-Dimethyl-Thiazol-5-Yl)-Pyrimidin-2-Ylamino]-Phenol PHENYLAMINOIMIDAZO(1,2-ALPHA)PYRIDINE OLOMOUCINE II TRIAZOLOPYRIMIDINE Bosutinib 4-[(7-OXO-7H-THIAZOLO[5,4-E]INDOL-8-YLMETHYL)-AMINO]-N-PYRIDIN-2-YL-BENZENESULFONAMIDE (13R,15S)-13-METHYL-16-OXA-8,9,12,22,24-PENTAAZAHEXACYCLO[15.6.2.16,9.1,12,15.0,2,7.0,21,25]HEPTACOSA-1(24),2,4,6,17(25),18,20-HEPTAENE-23,26-DIONE N-(3-CYCLOPROPYL-1H-PYRAZOL-5-YL)-2-(2-NAPHTHYL)ACETAMIDE 2-ANILINO-6-CYCLOHEXYLMETHOXYPURINE 1-(5-OXO-2,3,5,9B-TETRAHYDRO-1H-PYRROLO[2,1-A]ISOINDOL-9-YL)-3-(5-PYRROLIDIN-2-YL-1H-PYRAZOL-3-YL)-UREA (5-phenyl-7-(pyridin-3-ylmethylamino)pyrazolo[1,5-a]pyrimidin-3-yl)methanol 2-(3,4-DIHYDROXYPHENYL)-8-(1,1-DIOXIDOISOTHIAZOLIDIN-2-YL)-3-HYDROXY-6-METHYL-4H-CHROMEN-4-ONE (2R)-1-(DIMETHYLAMINO)-3-{4-[(6-{[2-FLUORO-5-(TRIFLUOROMETHYL)PHENYL]AMINO}PYRIMIDIN-4-YL)AMINO]PHENOXY}PROPAN-2-OL 5-(2,3-dichlorophenyl)-N-(pyridin-4-ylmethyl)-3-thiocyanatopyrazolo[1,5-a]pyrimidin-7-amine O6-CYCLOHEXYLMETHOXY-2-(4\'-SULPHAMOYLANILINO) PURINE (2S)-N-[(3Z)-5-CYCLOPROPYL-3H-PYRAZOL-3-YLIDENE]-2-[4-(2-OXOIMIDAZOLIDIN-1-YL)PHENYL]PROPANAMIDE 5-[(2-AMINOETHYL)AMINO]-6-FLUORO-3-(1H-PYRROL-2-YL)BENZO[CD]INDOL-2(1H)-ONE N-cyclopropyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine 3-((3-bromo-5-o-tolylpyrazolo[1,5-a]pyrimidin-7-ylamino)methyl)pyridine 1-oxide 6-CYCLOHEXYLMETHOXY-2-(3\'-CHLOROANILINO) PURINE 3-bromo-5-phenyl-N-(pyridin-4-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine N-[5-(1,1-DIOXIDOISOTHIAZOLIDIN-2-YL)-1H-INDAZOL-3-YL]-2-(4-PIPERIDIN-1-YLPHENYL)ACETAMIDE (3R)-3-(aminomethyl)-9-methoxy-1,2,3,4-tetrahydro-5H-[1]benzothieno[3,2-e][1,4]diazepin-5-one 5-[5,6-BIS(METHYLOXY)-1H-BENZIMIDAZOL-1-YL]-3-{[1-(2-CHLOROPHENYL)ETHYL]OXY}-2-THIOPHENECARBOXAMIDE (2Z)-5\'-BROMO-2,3\'-BIINDOLE-2\',3(1H,1\'H)-DIONE AMMONIATE (2S)-1-{4-[(4-ANILINO-5-BROMOPYRIMIDIN-2-YL)AMINO]PHENOXY}-3-(DIMETHYLAMINO)PROPAN-2-OL (2R)-1-{4-[(4-ANILINO-5-BROMOPYRIMIDIN-2-YL)AMINO]PHENOXY}-3-(DIMETHYLAMINO)PROPAN-2-OL 2-IMINO-5-(1-PYRIDIN-2-YL-METH-(E)-YLIDENE)-1,3-THIAZOLIDIN-4-ONE 4-{5-[(Z)-(2,4-DIOXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}BENZENESULFONAMIDE 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]-2-FURYL}-N-METHYLBENZENESULFONAMIDE 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}BENZENESULFONAMIDE 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}-2-(TRIFLUOROMETHYL)BENZENESULFONAMIDE 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}BENZOIC ACID 4-{5-[(1Z)-1-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)ETHYL]-2-FURYL}BENZENESULFONAMIDE N-[4-(2,4-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YL]-N\',N\'-DIMETHYL-BENZENE-1,4-DIAMINE (5Z)-5-(3-BROMOCYCLOHEXA-2,5-DIEN-1-YLIDENE)-N-(PYRIDIN-4-YLMETHYL)-1,5-DIHYDROPYRAZOLO[1,5-A]PYRIMIDIN-7-AMINE 6-(3,4-DIHYDROXYBENZYL)-3-ETHYL-1-(2,4,6-TRICHLOROPHENYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4(5H)-ONE 6-(3-AMINOPHENYL)-N-(TERT-BUTYL)-2-(TRIFLUOROMETHYL)QUINAZOLIN-4-AMINE 2-(4-(AMINOMETHYL)PIPERIDIN-1-YL)-N-(3_CYCLOHEXYL-4-OXO-2,4-DIHYDROINDENO[1,2-C]PYRAZOL-5-YL)ACETAMIDE 1-(3-(2,4-DIMETHYLTHIAZOL-5-YL)-4-OXO-2,4-DIHYDROINDENO[1,2-C]PYRAZOL-5-YL)-3-(4-METHYLPIPERAZIN-1-YL)UREA 4-{[5-(CYCLOHEXYLMETHOXY)[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL]AMINO}BENZENESULFONAMIDE 4-{[5-(CYCLOHEXYLAMINO)[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL]AMINO}BENZENESULFONAMIDE 4-({5-[(4-AMINOCYCLOHEXYL)AMINO][1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL}AMINO)BENZENESULFONAMIDE 4-{[5-(CYCLOHEXYLOXY)[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL]AMINO}BENZENESULFONAMIDE 4-[(E)-(3,5-DIAMINO-1H-PYRAZOL-4-YL)DIAZENYL]PHENOL (2R)-1-[4-({4-[(2,5-DICHLOROPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENOXY]-3-(DIMETHYLAMINO)PROPAN-2-OL (2S)-1-[4-({6-[(2,6-DIFLUOROPHENYL)AMINO]PYRIMIDIN-4-YL}AMINO)PHENOXY]-3-(DIMETHYLAMINO)PROPAN-2-OL (2S)-1-[4-({4-[(2,5-DICHLOROPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENOXY]-3-(DIMETHYLAMINO)PROPAN-2-OL (2R)-1-[4-({6-[(2,6-DIFLUOROPHENYL)AMINO]PYRIMIDIN-4-YL}AMINO)PHENOXY]-3-(DIMETHYLAMINO)PROPAN-2-OL N-(2-METHOXYETHYL)-4-({4-[2-METHYL-1-(1-METHYLETHYL)-1H-IMIDAZOL-5-YL]PYRIMIDIN-2-YL}AMINO)BENZENESULFONAMIDE 4-{[4-(1-CYCLOPROPYL-2-METHYL-1H-IMIDAZOL-5-YL)PYRIMIDIN-2-YL]AMINO}-N-METHYLBENZENESULFONAMIDE 1-(3,5-DICHLOROPHENYL)-5-METHYL-1H-1,2,4-TRIAZOLE-3-CARBOXYLIC ACID 1-(DIMETHYLAMINO)-3-(4-{{4-(2-METHYLIMIDAZO[1,2-A]PYRIDIN-3-YL)PYRIMIDIN-2-YL]AMINO}PHENOXY)PROPAN-2-OL N-(4-{[(3S)-3-(dimethylamino)pyrrolidin-1-yl]carbonyl}phenyl)-5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]pyrimidin-2-amine 2-{4-[4-({4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]pyrimidin-2-yl}amino)phenyl]piperazin-1-yl}-2-oxoethanol N-[3-(1H-BENZIMIDAZOL-2-YL)-1H-PYRAZOL-4-YL]BENZAMIDE (4-AMINO-2-{[1-(METHYLSULFONYL)PIPERIDIN-4-YL]AMINO}PYRIMIDIN-5-YL)(2,3-DIFLUORO-6-METHOXYPHENYL)METHANONE N-METHYL-4-{[(2-OXO-1,2-DIHYDRO-3H-INDOL-3-YLIDENE)METHYL]AMINO}BENZENESULFONAMIDE N-METHYL-{4-[2-(7-OXO-6,7-DIHYDRO-8H-[1,3]THIAZOLO[5,4-E]INDOL-8-YLIDENE)HYDRAZINO]PHENYL}METHANESULFONAMIDE 3-{[(2,2-DIOXIDO-1,3-DIHYDRO-2-BENZOTHIEN-5-YL)AMINO]METHYLENE}-5-(1,3-OXAZOL-5-YL)-1,3-DIHYDRO-2H-INDOL-2-ONE 4-{[(2-OXO-1,2-DIHYDRO-3H-INDOL-3-YLIDENE)METHYL]AMINO}-N-(1,3-THIAZOL-2-YL)BENZENESULFONAMIDE 3-{[4-([AMINO(IMINO)METHYL]AMINOSULFONYL)ANILINO]METHYLENE}-2-OXO-2,3-DIHYDRO-1H-INDOLE 5-hydroxynaphthalene-1-sulfonamide N-(4-sulfamoylphenyl)-1H-indazole-3-carboxamide 4-[(6-chloropyrazin-2-yl)amino]benzenesulfonamide N-phenyl-1H-pyrazole-3-carboxamide 4-(acetylamino)-N-(4-fluorophenyl)-1H-pyrazole-3-carboxamide (4E)-N-(4-fluorophenyl)-4-[(phenylcarbonyl)imino]-4H-pyrazole-3-carboxamide {[(2,6-difluorophenyl)carbonyl]amino}-N-(4-fluorophenyl)-1H-pyrazole-3-carboxamide 5-chloro-7-[(1-methylethyl)amino]pyrazolo[1,5-a]pyrimidine-3-carbonitrile 5-[(4-AMINOCYCLOHEXYL)AMINO]-7-(PROPAN-2-YLAMINO)PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBONITRILE 4-{[(2,6-difluorophenyl)carbonyl]amino}-N-[(3S)-piperidin-3-yl]-1H-pyrazole-3-carboxamide 4-{[(2,6-dichlorophenyl)carbonyl]amino}-N-piperidin-4-yl-1H-pyrazole-3-carboxamide 4-(4-methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-amine 4-(4-propoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-amine HYDROXY(OXO)(3-{[(2Z)-4-[3-(1H-1,2,4-TRIAZOL-1-YLMETHYL)PHENYL]PYRIMIDIN-2(5H)-YLIDENE]AMINO}PHENYL)AMMONIUM 4-METHYL-5-{(2E)-2-[(4-MORPHOLIN-4-YLPHENYL)IMINO]-2,5-DIHYDROPYRIMIDIN-4-YL}-1,3-THIAZOL-2-AMINE 6-CYCLOHEXYLMETHYLOXY-2-(4\'-HYDROXYANILINO)PURINE 4-(6-CYCLOHEXYLMETHOXY-9H-PURIN-2-YLAMINO)--BENZAMIDE 6-(CYCLOHEXYLMETHOXY)-8-ISOPROPYL-9H-PURIN-2-AMINE 3-(6-CYCLOHEXYLMETHOXY-9H-PURIN-2-YLAMINO)-BENZENESULFONAMIDE (2R)-2-{[4-(benzylamino)-8-(1-methylethyl)pyrazolo[1,5-a][1,3,5]triazin-2-yl]amino}butan-1-ol 3-({2-[(4-{[6-(CYCLOHEXYLMETHOXY)-9H-PURIN-2-YL]AMINO}PHENYL)SULFONYL]ETHYL}AMINO)PROPAN-1-OL 6-CYCLOHEXYLMETHYLOXY-5-NITROSO-PYRIMIDINE-2,4-DIAMINE 1-methyl-8-(phenylamino)-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxylic acid 6-BROMO-13-THIA-2,4,8,12,19-PENTAAZATRICYCLO[12.3.1.1~3,7~]NONADECA-1(18),3(19),4,6,14,16-HEXAENE 13,13-DIOXIDE (2R)-2-({9-(1-methylethyl)-6-[(4-pyridin-2-ylbenzyl)amino]-9H-purin-2-yl}amino)butan-1-ol 1-[4-(AMINOSULFONYL)PHENYL]-1,6-DIHYDROPYRAZOLO[3,4-E]INDAZOLE-3-CARBOXAMIDE 5-(2,3-dichlorophenyl)-N-(pyridin-4-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine 6-(2-fluorophenyl)-N-(pyridin-3-ylmethyl)imidazo[1,2-a]pyrazin-8-amine 3-methyl-N-(pyridin-4-ylmethyl)imidazo[1,2-a]pyrazin-8-amine 5-(2-fluorophenyl)-N-(pyridin-4-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine 3-bromo-5-phenyl-N-(pyridin-3-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine 3-bromo-5-phenyl-N-(pyrimidin-5-ylmethyl)pyrazolo[1,5-a]pyridin-7-amine 3-bromo-6-phenyl-N-(pyrimidin-5-ylmethyl)imidazo[1,2-a]pyridin-8-amine N-((2-aminopyrimidin-5-yl)methyl)-5-(2,6-difluorophenyl)-3-ethylpyrazolo[1,5-a]pyrimidin-7-amine 3-cyclopropyl-5-phenyl-N-(pyridin-3-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine 4-{[4-AMINO-6-(CYCLOHEXYLMETHOXY)-5-NITROSOPYRIMIDIN-2-YL]AMINO}BENZAMIDE 4-[(5-ISOPROPYL-1,3-THIAZOL-2-YL)AMINO]BENZENESULFONAMIDE N-(5-ISOPROPYL-THIAZOL-2-YL)-2-PYRIDIN-3-YL-ACETAMIDE 9-amino-5-(2-aminopyrimidin-4-yl)pyrido[3\',2\':4,5]pyrrolo[1,2-c]pyrimidin-4-ol N-(3-METHYLBUT-2-EN-1-YL)-9H-PURIN-6-AMINE
CDK4 and BAG6	cyclin-dependent kinase 4	BCL2-associated athanogene 6	Meiotic recombination Chromatin organization Ubiquitin-dependent degradation of Cyclin D Cellular Senescence G1 Phase Senescence-Associated Secretory Phenotype (SASP) S Phase Oncogene Induced Senescence Cell Cycle, Mitotic Ubiquitin-dependent degradation of Cyclin D1 RMTs methylate histone arginines Cyclin D associated events in G1 Chromatin modifying enzymes Oxidative Stress Induced Senescence Transcriptional regulation of white adipocyte differentiation Mitotic G1-G1/S phases
CDK5 and KIF26B	cyclin-dependent kinase 5	kinesin family member 26B	Signaling by GPCR Axon guidance Semaphorin interactions Opioid Signalling DARPP-32 events CRMPs in Sema3A signaling Factors involved in megakaryocyte development and platelet production		Indirubin-3\'-Monoxime Olomoucine Hymenialdisine SU9516 Flavopiridol Alsterpaullone 6-PHENYL[5H]PYRROLO[2,3-B]PYRAZINE
CDK5 and GRIN2A	cyclin-dependent kinase 5	glutamate receptor, ionotropic, N-methyl D-aspartate 2A	Signaling by GPCR Axon guidance Semaphorin interactions Opioid Signalling DARPP-32 events CRMPs in Sema3A signaling Factors involved in megakaryocyte development and platelet production	Activation of NMDA receptor upon glutamate binding and postsynaptic events CREB phosphorylation through the activation of CaMKII CREB phosphorylation through the activation of Ras Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell Unblocking of NMDA receptor, glutamate binding and activation Ras activation uopn Ca2+ infux through NMDA receptor Post NMDA receptor activation events Transmission across Chemical Synapses	Indirubin-3\'-Monoxime Olomoucine Hymenialdisine SU9516 Flavopiridol Alsterpaullone 6-PHENYL[5H]PYRROLO[2,3-B]PYRAZINE	L-Glutamic Acid Glycine Meperidine Felbamate Memantine Halothane Tenocyclidine
CDK5 and BAG6	cyclin-dependent kinase 5	BCL2-associated athanogene 6	Signaling by GPCR Axon guidance Semaphorin interactions Opioid Signalling DARPP-32 events CRMPs in Sema3A signaling Factors involved in megakaryocyte development and platelet production		Indirubin-3\'-Monoxime Olomoucine Hymenialdisine SU9516 Flavopiridol Alsterpaullone 6-PHENYL[5H]PYRROLO[2,3-B]PYRAZINE
CDK6 and KIF26B	cyclin-dependent kinase 6	kinesin family member 26B	Cyclin D associated events in G1 Oxidative Stress Induced Senescence G1 Phase Cellular Senescence Senescence-Associated Secretory Phenotype (SASP) Oncogene Induced Senescence Mitotic G1-G1/S phases Cell Cycle, Mitotic
CDK7 and CTD	cyclin-dependent kinase 7	Coats disease	RNA Polymerase II Promoter Escape Formation of HIV-1 elongation complex containing HIV-1 Tat RNA Polymerase II Transcription Pre-Initiation And Promoter Opening RNA Polymerase I Chain Elongation RNA Polymerase I, RNA Polymerase III, and Mitochondrial Transcription Tat-mediated elongation of the HIV-1 transcript Cyclin E associated events during G1/S transition Formation of transcription-coupled NER (TC-NER) repair complex Dual incision reaction in TC-NER NoRC negatively regulates rRNA expression G1/S Transition Mitotic G1-G1/S phases S Phase Late Phase of HIV Life Cycle Formation of RNA Pol II elongation complex Global Genomic NER (GG-NER) RNA Polymerase II Transcription Initiation And Promoter Clearance Cyclin A:Cdk2-associated events at S phase entry Mitotic G2-G2/M phases Transcription of the HIV genome Nucleotide Excision Repair RNA Polymerase II Transcription RNA Polymerase I Transcription Initiation HIV Infection RNA Polymerase I Promoter Clearance Formation of the Early Elongation Complex G2/M Transition RNA Pol II CTD phosphorylation and interaction with CE RNA Polymerase II Pre-transcription Events HIV Transcription Initiation HIV Life Cycle RNA Pol II CTD phosphorylation and interaction with CE Cyclin A/B1 associated events during G2/M transition RNA Polymerase II HIV Promoter Escape HIV Transcription Elongation Dual incision reaction in GG-NER RNA Polymerase I Transcription mRNA Capping RNA Polymerase I Promoter Escape RNA Polymerase I Transcription Termination G1 Phase Epigenetic regulation of gene expression Negative epigenetic regulation of rRNA expression Cell Cycle, Mitotic Cyclin D associated events in G1 Transcription-coupled NER (TC-NER) Formation of HIV elongation complex in the absence of HIV Tat Formation of the HIV-1 Early Elongation Complex Formation of incision complex in GG-NER RNA Polymerase II Transcription Initiation RNA Polymerase II Transcription Elongation		Phosphonothreonine Flavopiridol
CDK7 and HLA-DQA1	cyclin-dependent kinase 7	major histocompatibility complex, class II, DQ alpha 1	RNA Polymerase II Promoter Escape Formation of HIV-1 elongation complex containing HIV-1 Tat RNA Polymerase II Transcription Pre-Initiation And Promoter Opening RNA Polymerase I Chain Elongation RNA Polymerase I, RNA Polymerase III, and Mitochondrial Transcription Tat-mediated elongation of the HIV-1 transcript Cyclin E associated events during G1/S transition Formation of transcription-coupled NER (TC-NER) repair complex Dual incision reaction in TC-NER NoRC negatively regulates rRNA expression G1/S Transition Mitotic G1-G1/S phases S Phase Late Phase of HIV Life Cycle Formation of RNA Pol II elongation complex Global Genomic NER (GG-NER) RNA Polymerase II Transcription Initiation And Promoter Clearance Cyclin A:Cdk2-associated events at S phase entry Mitotic G2-G2/M phases Transcription of the HIV genome Nucleotide Excision Repair RNA Polymerase II Transcription RNA Polymerase I Transcription Initiation HIV Infection RNA Polymerase I Promoter Clearance Formation of the Early Elongation Complex G2/M Transition RNA Pol II CTD phosphorylation and interaction with CE RNA Polymerase II Pre-transcription Events HIV Transcription Initiation HIV Life Cycle RNA Pol II CTD phosphorylation and interaction with CE Cyclin A/B1 associated events during G2/M transition RNA Polymerase II HIV Promoter Escape HIV Transcription Elongation Dual incision reaction in GG-NER RNA Polymerase I Transcription mRNA Capping RNA Polymerase I Promoter Escape RNA Polymerase I Transcription Termination G1 Phase Epigenetic regulation of gene expression Negative epigenetic regulation of rRNA expression Cell Cycle, Mitotic Cyclin D associated events in G1 Transcription-coupled NER (TC-NER) Formation of HIV elongation complex in the absence of HIV Tat Formation of the HIV-1 Early Elongation Complex Formation of incision complex in GG-NER RNA Polymerase II Transcription Initiation RNA Polymerase II Transcription Elongation	Generation of second messenger molecules Downstream TCR signaling Costimulation by the CD28 family Translocation of ZAP-70 to Immunological synapse Interferon Signaling Cytokine Signaling in Immune system Interferon gamma signaling TCR signaling MHC class II antigen presentation PD-1 signaling Phosphorylation of CD3 and TCR zeta chains Adaptive Immune System	Phosphonothreonine Flavopiridol
CDK7 and CTDP1	cyclin-dependent kinase 7	CTD (carboxy-terminal domain, RNA polymerase II, polypeptide A) phosphatase, subunit 1	RNA Polymerase II Promoter Escape Formation of HIV-1 elongation complex containing HIV-1 Tat RNA Polymerase II Transcription Pre-Initiation And Promoter Opening RNA Polymerase I Chain Elongation RNA Polymerase I, RNA Polymerase III, and Mitochondrial Transcription Tat-mediated elongation of the HIV-1 transcript Cyclin E associated events during G1/S transition Formation of transcription-coupled NER (TC-NER) repair complex Dual incision reaction in TC-NER NoRC negatively regulates rRNA expression G1/S Transition Mitotic G1-G1/S phases S Phase Late Phase of HIV Life Cycle Formation of RNA Pol II elongation complex Global Genomic NER (GG-NER) RNA Polymerase II Transcription Initiation And Promoter Clearance Cyclin A:Cdk2-associated events at S phase entry Mitotic G2-G2/M phases Transcription of the HIV genome Nucleotide Excision Repair RNA Polymerase II Transcription RNA Polymerase I Transcription Initiation HIV Infection RNA Polymerase I Promoter Clearance Formation of the Early Elongation Complex G2/M Transition RNA Pol II CTD phosphorylation and interaction with CE RNA Polymerase II Pre-transcription Events HIV Transcription Initiation HIV Life Cycle RNA Pol II CTD phosphorylation and interaction with CE Cyclin A/B1 associated events during G2/M transition RNA Polymerase II HIV Promoter Escape HIV Transcription Elongation Dual incision reaction in GG-NER RNA Polymerase I Transcription mRNA Capping RNA Polymerase I Promoter Escape RNA Polymerase I Transcription Termination G1 Phase Epigenetic regulation of gene expression Negative epigenetic regulation of rRNA expression Cell Cycle, Mitotic Cyclin D associated events in G1 Transcription-coupled NER (TC-NER) Formation of HIV elongation complex in the absence of HIV Tat Formation of the HIV-1 Early Elongation Complex Formation of incision complex in GG-NER RNA Polymerase II Transcription Initiation RNA Polymerase II Transcription Elongation	Formation of HIV-1 elongation complex containing HIV-1 Tat RNA Polymerase II Transcription Abortive elongation of HIV-1 transcript in the absence of Tat HIV Infection Formation of the Early Elongation Complex Tat-mediated elongation of the HIV-1 transcript Tat-mediated HIV elongation arrest and recovery RNA Polymerase II Pre-transcription Events Late Phase of HIV Life Cycle Pausing and recovery of Tat-mediated HIV elongation Formation of RNA Pol II elongation complex HIV elongation arrest and recovery HIV Life Cycle Pausing and recovery of HIV elongation Formation of HIV elongation complex in the absence of HIV Tat Formation of the HIV-1 Early Elongation Complex HIV Transcription Elongation Transcription of the HIV genome RNA Polymerase II Transcription Elongation	Phosphonothreonine Flavopiridol
CDK8 and CTD	cyclin-dependent kinase 8	Coats disease	Loss of Function of TGFBR2 in Cancer PPARA activates gene expression Signaling by NOTCH1 HD Domain Mutants in Cancer Metabolism of lipids and lipoproteins Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer SMAD2/3 MH2 Domain Mutants in Cancer TGFBR1 LBD Mutants in Cancer SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant Generic Transcription Pathway Signaling by NOTCH1 Transcriptional regulation of white adipocyte differentiation Signaling by NOTCH1 in Cancer Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants FBXW7 Mutants and NOTCH1 in Cancer TGFBR2 MSI Frameshift Mutants in Cancer Fatty acid, triacylglycerol, and ketone body metabolism SMAD2/3 Phosphorylation Motif Mutants in Cancer Loss of Function of SMAD2/3 in Cancer Signaling by NOTCH TGFBR2 Kinase Domain Mutants in Cancer Loss of Function of SMAD4 in Cancer TGFBR1 KD Mutants in Cancer Loss of Function of TGFBR1 in Cancer NOTCH1 Intracellular Domain Regulates Transcription Signaling by TGF-beta Receptor Complex in Cancer Signaling by TGF-beta Receptor Complex Signaling by NOTCH1 PEST Domain Mutants in Cancer Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha) Constitutive Signaling by NOTCH1 PEST Domain Mutants SMAD4 MH2 Domain Mutants in Cancer
CDK8 and CTDP1	cyclin-dependent kinase 8	CTD (carboxy-terminal domain, RNA polymerase II, polypeptide A) phosphatase, subunit 1	Loss of Function of TGFBR2 in Cancer PPARA activates gene expression Signaling by NOTCH1 HD Domain Mutants in Cancer Metabolism of lipids and lipoproteins Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer SMAD2/3 MH2 Domain Mutants in Cancer TGFBR1 LBD Mutants in Cancer SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant Generic Transcription Pathway Signaling by NOTCH1 Transcriptional regulation of white adipocyte differentiation Signaling by NOTCH1 in Cancer Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants FBXW7 Mutants and NOTCH1 in Cancer TGFBR2 MSI Frameshift Mutants in Cancer Fatty acid, triacylglycerol, and ketone body metabolism SMAD2/3 Phosphorylation Motif Mutants in Cancer Loss of Function of SMAD2/3 in Cancer Signaling by NOTCH TGFBR2 Kinase Domain Mutants in Cancer Loss of Function of SMAD4 in Cancer TGFBR1 KD Mutants in Cancer Loss of Function of TGFBR1 in Cancer NOTCH1 Intracellular Domain Regulates Transcription Signaling by TGF-beta Receptor Complex in Cancer Signaling by TGF-beta Receptor Complex Signaling by NOTCH1 PEST Domain Mutants in Cancer Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha) Constitutive Signaling by NOTCH1 PEST Domain Mutants SMAD4 MH2 Domain Mutants in Cancer	Formation of HIV-1 elongation complex containing HIV-1 Tat RNA Polymerase II Transcription Abortive elongation of HIV-1 transcript in the absence of Tat HIV Infection Formation of the Early Elongation Complex Tat-mediated elongation of the HIV-1 transcript Tat-mediated HIV elongation arrest and recovery RNA Polymerase II Pre-transcription Events Late Phase of HIV Life Cycle Pausing and recovery of Tat-mediated HIV elongation Formation of RNA Pol II elongation complex HIV elongation arrest and recovery HIV Life Cycle Pausing and recovery of HIV elongation Formation of HIV elongation complex in the absence of HIV Tat Formation of the HIV-1 Early Elongation Complex HIV Transcription Elongation Transcription of the HIV genome RNA Polymerase II Transcription Elongation
CDK9 and CTDP1	cyclin-dependent kinase 9	CTD (carboxy-terminal domain, RNA polymerase II, polypeptide A) phosphatase, subunit 1	Loss of Function of TGFBR2 in Cancer Formation of HIV-1 elongation complex containing HIV-1 Tat RNA Polymerase II Transcription HIV Infection SMAD2/3 MH2 Domain Mutants in Cancer Tat-mediated elongation of the HIV-1 transcript Tat-mediated HIV elongation arrest and recovery TGFBR1 LBD Mutants in Cancer RNA Polymerase II Pre-transcription Events SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer HIV elongation arrest and recovery HIV Life Cycle Generic Transcription Pathway HIV Transcription Elongation TGFBR2 MSI Frameshift Mutants in Cancer SMAD2/3 Phosphorylation Motif Mutants in Cancer Loss of Function of SMAD2/3 in Cancer TGFBR2 Kinase Domain Mutants in Cancer Host Interactions of HIV factors Loss of Function of SMAD4 in Cancer Interactions of Tat with host cellular proteins TGFBR1 KD Mutants in Cancer Pausing and recovery of Tat-mediated HIV elongation Loss of Function of TGFBR1 in Cancer Late Phase of HIV Life Cycle Formation of RNA Pol II elongation complex Signaling by TGF-beta Receptor Complex Signaling by TGF-beta Receptor Complex in Cancer Pausing and recovery of HIV elongation Formation of HIV elongation complex in the absence of HIV Tat Transcription of the HIV genome SMAD4 MH2 Domain Mutants in Cancer RNA Polymerase II Transcription Elongation	Formation of HIV-1 elongation complex containing HIV-1 Tat RNA Polymerase II Transcription Abortive elongation of HIV-1 transcript in the absence of Tat HIV Infection Formation of the Early Elongation Complex Tat-mediated elongation of the HIV-1 transcript Tat-mediated HIV elongation arrest and recovery RNA Polymerase II Pre-transcription Events Late Phase of HIV Life Cycle Pausing and recovery of Tat-mediated HIV elongation Formation of RNA Pol II elongation complex HIV elongation arrest and recovery HIV Life Cycle Pausing and recovery of HIV elongation Formation of HIV elongation complex in the absence of HIV Tat Formation of the HIV-1 Early Elongation Complex HIV Transcription Elongation Transcription of the HIV genome RNA Polymerase II Transcription Elongation

Search Results for: Schizophrenia